These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

617 related items for PubMed ID: 19436668

  • 1. Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia.
    Johansen OE, Vanberg PJ, Kilhovd BK, Jørgensen AP.
    Vasc Health Risk Manag; 2009; 5(1):121-8. PubMed ID: 19436668
    [Abstract] [Full Text] [Related]

  • 2. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.
    Hemmingsen B, Metzendorf MI, Richter B.
    Cochrane Database Syst Rev; 2021 Mar 04; 3(3):CD013498. PubMed ID: 33662147
    [Abstract] [Full Text] [Related]

  • 3. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
    Semlitsch T, Engler J, Siebenhofer A, Jeitler K, Berghold A, Horvath K.
    Cochrane Database Syst Rev; 2020 Nov 09; 11(11):CD005613. PubMed ID: 33166419
    [Abstract] [Full Text] [Related]

  • 4. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart.
    Vague P, Selam JL, Skeie S, De Leeuw I, Elte JW, Haahr H, Kristensen A, Draeger E.
    Diabetes Care; 2003 Mar 09; 26(3):590-6. PubMed ID: 12610006
    [Abstract] [Full Text] [Related]

  • 5. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen.
    Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J.
    Clin Ther; 2004 May 09; 26(5):724-36. PubMed ID: 15220016
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus.
    Mullins P, Sharplin P, Yki-Jarvinen H, Riddle MC, Haring HU.
    Clin Ther; 2007 Aug 09; 29(8):1607-19. PubMed ID: 17919543
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
    Heller S, Koenen C, Bode B.
    Clin Ther; 2009 Oct 09; 31(10):2086-97. PubMed ID: 19922879
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Comparison of the efficacy and safety of insulin glargine and insulin detemir with NPH insulin in children and adolescents with type 1 diabetes mellitus receiving intensive insulin therapy.
    Dündar BN, Dündar N, Eren E.
    J Clin Res Pediatr Endocrinol; 2009 Oct 09; 1(4):181-7. PubMed ID: 21274293
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy.
    Fulcher GR, Gilbert RE, Yue DK.
    Intern Med J; 2005 Sep 09; 35(9):536-42. PubMed ID: 16105155
    [Abstract] [Full Text] [Related]

  • 14. The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes.
    Standl E, Lang H, Roberts A.
    Diabetes Technol Ther; 2004 Oct 09; 6(5):579-88. PubMed ID: 15628811
    [Abstract] [Full Text] [Related]

  • 15. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes.
    Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA.
    Diabetologia; 2004 Apr 09; 47(4):622-9. PubMed ID: 15298338
    [Abstract] [Full Text] [Related]

  • 16. Daily insulin doses and injection frequencies of neutral protamine hagedorn (NPH) insulin, insulin detemir and insulin glargine in type 1 and type 2 diabetes: a multicenter analysis of 51 964 patients from the German/Austrian DPV-wiss database.
    Laubner K, Molz K, Kerner W, Karges W, Lang W, Dapp A, Schütt M, Best F, Seufert J, Holl RW.
    Diabetes Metab Res Rev; 2014 Jul 09; 30(5):395-404. PubMed ID: 24302583
    [Abstract] [Full Text] [Related]

  • 17. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study.
    Meneghini LF, Rosenberg KH, Koenen C, Merilainen MJ, Lüddeke HJ.
    Diabetes Obes Metab; 2007 May 09; 9(3):418-27. PubMed ID: 17391170
    [Abstract] [Full Text] [Related]

  • 18. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial.
    Fritsche A, Schweitzer MA, Häring HU, 4001 Study Group.
    Ann Intern Med; 2003 Jun 17; 138(12):952-9. PubMed ID: 12809451
    [Abstract] [Full Text] [Related]

  • 19. An update on the treatment of type 1 and type 2 diabetes mellitus: focus on insulin detemir, a long-acting human insulin analog.
    Raslova K.
    Vasc Health Risk Manag; 2010 Jun 01; 6():399-410. PubMed ID: 20539842
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.